// App-Quantinova.ai

590 : Benefit of adjuvant chemotherapy and/or trastuzumab in T1ab node-negative human epidermal growth factor receptor 2positive breast carcinomas: Results of a national multi-institutional study.

Researchers

Presenter

  • Alexandre de Nonneville

Principal Investigators

  • Anthony Goncalves

  • Christophe Zemmour

  • Jean-Marc Classe

  • Monique Cohen

  • Eric Lambaudie

  • Fabien Reyal

  • Sylvia Giard

  • Roman Rouzier

  • Richard Villet

  • Jean-Marie Boher

  • Gilles Houvenaeghel

Medical Centers

  • Institut Paoli-Calmettes, Marseille, France

  • Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

  • Institut Rene Gauducheau, Nantes, Nantes, France

  • Institut Curie, Paris Cedex, France

  • Department of Surgery, Centre Oscar Lambret, Lille, France

  • Institut Curie, Paris Cedex, France

  • Hopital des Diaconesses, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved